WO1998030228A1 - Compounds and their combinations for the treatment of influenza infection - Google Patents
Compounds and their combinations for the treatment of influenza infection Download PDFInfo
- Publication number
- WO1998030228A1 WO1998030228A1 PCT/US1998/000380 US9800380W WO9830228A1 WO 1998030228 A1 WO1998030228 A1 WO 1998030228A1 US 9800380 W US9800380 W US 9800380W WO 9830228 A1 WO9830228 A1 WO 9830228A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutically acceptable
- acid
- influenza virus
- pharmaceutical composition
- vitamin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Definitions
- Influenza virus is a large RNA virus having a core of helical symmetry containing a soluble nucleoprotein antigen.
- the virion has a membrane envelope with spikes containing two viral glycoproteins, one having hemagglutinating activity (HA) and one having neuraminidase activity (NA).
- Influenza virus attaches to a specific glycoprotein receptor for the hemagglutinin on the cell surface.
- the virus possesses an unusual genomic structure of RNA segments, which reshuffle upon each cycle of infection.
- Influenza is a virus of the respiratory tract, and is an etiological agent of acute bronchitis, pneumonia, croup, and influenza.
- Current therapy includes amantadine, which has various undesirable side effects.
- GSH glutathione
- GSSG glutathione disulfide
- N-acetyl-L-cysteine or ascorbate- 2-phosphate, or any combination thereof, with or without antioxidants is suitable for the prevention or treatment of influenza virus infection.
- Glutathione is the tripeptide gamma-L-Glu-L-Cys-Gly, of the structure
- GSH is a biological reducing agent in thiol-dependent reactions. As an exogenously supplied drug, it potentiates and enhances the efficacy of various antineoplastic agents, presumably through nucleophilic thioether formation or oxidation-reduction reactions. See, e.g., Arrick, B.A. et al. Cancer Research 44:4224 (1984).
- Glutathione is an essential compound in the gamma-glutamyl cycle, which probably functions to transport amino acids through the cell membrane. Glutathione is also known to act as a cofactor in a variety of enzymatic reactions, including the glyoxylase reaction, the cis-trans isomerization of maleylacetoacetate to fumarylacetoacetate, and the formaldehyde dehydrogenase reaction.
- GSH Glutathione disulfide
- GSH Glutathione disulfide
- N-Acetyl-L-cysteine is commonly known as a mucolytic agent. It also functions as a reducing sulfur compound in certain protein purifications, an agent for treating lower respiratory tract infections in children, as well as chronic bronchitis, HIV infection, chronic cardiorespiratory disorders and fulminant hepatic failure. It is also known as a disinfectant for Hepatitis B virus, and an agent that enhances the response to interferon-alpha in chronic Hepatitis C cases. Ascorbate-2-phosphate is a stable derivative of ascorbic acid
- vitamin C (vitamin C). It has the structure
- Vitamin C is widely used as an ingredient of cosmetic compositions, such as skin creams and lotions, as well as a common dietary supplement.
- cosmetic compositions such as skin creams and lotions
- a variety of unrelated uses are also known, including uses related to pickling and preservation of meat and seafood, improved dough for making breads, soy seasoning for fermented soybeans, sweetening agent, nerve growth factor potentiator, chemical decontaminant for a nuclear plant, a component in compositions for adding texture and color stability to frozen vegetables, an ingredient for an electroplating bath suitable for electroplating electronic parts, and part of a process for making fine palladiuum particles.
- the antiviral agents are supplied directly to cells to reduce infection and viral particle production.
- Current methods for prevention of influenza infection involve immunization, which is not completely effective, is costly and has associated risks.
- Glutathione, glutathione disulfide, N-acetyl-L-cysteine, ascorbate-2-phosphate, or any combination thereof are safe natural products for the treatment of influenza virus infection and also provide a novel approach to prevention.
- These compositions can be supplied directly to the epithelial cells which are the potential site of infection in a lozenge, drinking solution, mouth rinse or nasal spray.
- non-toxic compounds are suitable for the prevention or treatment of infection by the influenza virus, and include compositions comprising the tripeptide analog glutathione (GSH), its oxidized dimer glutathione disulfide (GSSG), ascorbate-2-phosphate, N-acetyl-L- cysteine, or combinations thereof. Delivery is preferably carried out in the form of lozenges, drinking solution, mouth rinse or nasal spray, for the purpose of coating the nasal passages and mucous membranes of the patient.
- GSH tripeptide analog glutathione
- GSSG oxidized dimer glutathione disulfide
- ascorbate-2-phosphate N-acetyl-L- cysteine
- Delivery is preferably carried out in the form of lozenges, drinking solution, mouth rinse or nasal spray, for the purpose of coating the nasal passages and mucous membranes of the patient.
- This invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising (a) one or more compounds selected from the group consisting of glutathione, glutathione disulfide, ascorbate-2 -phosphate and N-acetyl-L- cysteine, or pharmaceutically acceptable salt of any of these compounds; and (b) a pharmaceutically acceptable carrier, said composition useful in preventing or treating of influenza virus infection.
- One embodiment of the present invention relates to the pharmaceutical composition
- the pharmaceutical composition comprising (a) one or more compounds selected from the group consisting of glutathione, glutathione disulfide, ascorbate-2-phosphate and N-acetyl-L- cysteine, or pharmaceutically acceptable salt of any of these compounds;
- composition useful in preventing or treating of influenza virus infection.
- Another embodiment of the present invention relates to the pharmaceutical composition
- the pharmaceutical composition comprising (a) one or more compounds selected from the group consisting of glutathione, glutathione disulfide, ascorbate-2-phosphate and N-acetyl-L- cysteine, or pharmaceutically acceptable salt of any of these compounds;
- antioxidants selected from the group consisting of Vitamin A, Vitamin E, Vitamin K, Copper (as cupric oxide), Zinc (as zinc oxide), Iron (as ferrous salt), Selenium (sodium selenate), beta-carotene, polyphenol, catechin, quercetin, eriodictyol, carnosic acid, carnosol, rosmarrinic acid, caffeic acid, coumaric acid, cinnamic acid, Coenzyme Q10, Probucol, astaxanthin, lycopene, alpha-lipoate, and urate, or pharmaceutically acceptable salt of any such antioxidant; and (c) a pharmaceutically acceptable carrier, said composition useful in preventing or treating of influenza virus infection.
- Another embodiment of the same invention relates to the method of treating influenza virus infection, or preventing infection by influenza virus, by administering to a patient in need of such treatment a pharmaceutical composition comprising
- a pharmaceutically acceptable carrier relates to the method of treating influenza virus infection, or preventing infection by influenza virus, by administering to a patient in need of such treatment a pharmaceutical composition comprising (a) one or more compounds selected from the group consisting of glutathione, glutathione disulfide, ascorbate-2-phosphate and N-acetyl-L- cysteine, or pharmaceutically acceptable salt of any of these compounds;
- Another embodiment of the same invention relates to the method of treating influenza virus infection, or preventing infection by influenza virus, by administering to a patient in need of such treatment a pharmaceutical composition
- a pharmaceutical composition comprising (a) one or more compounds selected from the group consisting of glutathione, glutathione disulfide, ascorbate-2 -phosphate and N-acetyl-L- cysteine, or pharmaceutically acceptable salt of any of these compounds;
- antioxidants selected from the group consisting of Vitamin A, Vitamin E, Vitamin K, Copper (as cupric oxide), Zinc (as zinc oxide), Iron (as ferrous salt), Selenium (sodium selenate), beta-carotene, polyphenol, catechin, quercetin, eriodictyol, carnosic acid, carnosol, rosmarrinic acid, caffeic acid, coumaric acid, cinnamic acid, Coenzyme Q10, Probucol, astaxanthin, lycopene, alpha-lipoate, and urate, or pharmaceutically acceptable salt of any such antioxidant; and (c) a pharmaceutically acceptable carrier.
- antioxidants selected from the group consisting of Vitamin A, Vitamin E, Vitamin K, Copper (as cupric oxide), Zinc (as zinc oxide), Iron (as ferrous salt), Selenium (sodium selenate), beta-carotene, polyphenol, catechin, quercetin, eriodictyol
- Another embodiment of the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising (a) a compound selected from the group consisting of glutathione and glutathione disulfide, or pharmaceutically acceptable salt of any of these compounds; and
- composition useful in preventing or treating of influenza virus infection.
- composition useful in preventing or treating of influenza virus infection.
- antioxidants selected from the group consisting of Vitamin A, Vitamin E, Vitamin K, Copper (as cupric oxide), Zinc (as zinc oxide), Iron (as ferrous salt), Selenium (sodium selenate), beta-carotene, polyphenol, catechin, quercetin, eriodictyol, carnosic acid, carnosol, rosmarrinic acid, caffeic acid, coumaric acid, cinnamic acid, Coenzyme Q10, Probucol, astaxanthin, lycopene, alpha-lipoate, and urate, or pharmaceutically acceptable salt of any such antioxidant; and
- composition useful in preventing or treating of influenza virus infection.
- Another embodiment of the present invention relates to the method of treating influenza virus infection, or preventing infection by influenza virus, by administering to a patient in need of such treatment a pharmaceutical composition comprising
- Another embodiment of the present invention relates to the method of treating influenza virus infection, or preventing infection by influenza virus, by administering to a patient in need of such treatment a pharmaceutical composition comprising
- Another embodiment of the present invention relates to the method of treating influenza virus infection, or preventing infection by influenza virus, by administering to a patient in need of such treatment a pharmaceutical composition comprising
- antioxidants selected from the group consisting of Vitamin A, Vitamin E, Vitamin K, Copper (as cupric oxide), Zinc (as zinc oxide), Iron (as ferrous salt), Selenium (sodium selenate), beta-carotene, polyphenol, catechin, quercetin, eriodictyol, carnosic acid, carnosol, rosmarrinic acid, caffeic acid, coumaric acid, cinnamic acid, Coenzyme Q10, Probucol, astaxanthin, lycopene, alpha-lipoate, and urate, or pharmaceutically acceptable salt of any such antioxidant; and
- composition useful in preventing or treating of influenza virus infection.
- pharmaceutical composition comprising
- composition useful in preventing or treating of influenza virus infection.
- compositions comprising (a) ascorbate-2-phosphate or pharmaceutically acceptable salt thereof;
- antioxidants selected from the group consisting of Vitamin A, Vitamin E, Vitamin K, Copper (as cupric oxide), Zinc (as zinc oxide), Iron (as ferrous salt), Selenium (sodium selenate), beta-carotene, polyphenol, catechin, quercetin, eriodictyol, carnosic acid, carnosol, rosmarrinic acid, caffeic acid, coumaric acid, cinnamic acid, Coenzyme Q10, Probucol, astaxanthin, lycopene, alpha-lipoate, and urate, or pharmaceutically acceptable salt of any such antioxidant; and (c) a pharmaceutically acceptable carrier, said composition useful in preventing or treating of influenza virus infection.
- Another embodiment of the present invention is the method of treating influenza virus infection, or preventing infection by influenza virus, by administering to a patient in need of such treatment a pharmaceutical composition comprising
- Another embodiment of the present invention is the method of treating influenza virus infection, or preventing infection by influenza virus, by administering to a patient in need of such treatment a pharmaceutical composition comprising
- Another embodiment of the present invention is the method of treating influenza virus infection, or preventing infection by influenza virus, by administering to a patient in need of such treatment a pharmaceutical composition comprising
- antioxidants selected from the group consisting of Vitamin A, Vitamin E, Vitamin K, Copper (as cupric oxide), Zinc (as zinc oxide), Iron (as ferrous salt), Selenium (sodium selenate), beta-carotene, polyphenol, catechin, quercetin, eriodictyol, carnosic acid, carnosol, rosmarrinic acid, caffeic acid, coumaric acid, cinnamic acid, Coenzyme Q10, Probucol, astaxanthin, lycopene, alpha-lipoate, and urate, or pharmaceutically acceptable salt of any such antioxidant; and (c) a pharmaceutically acceptable carrier.
- Another embodiment of this invention relates to a pharmaceutical composition comprising
- composition useful in preventing or treating of influenza virus infection.
- N-acetyl-L-cysteine or pharmaceutically acceptable salt thereof;
- one or more antioxidants or pharmaceutically acceptable salt of any such antioxidant;
- composition useful in preventing or treating of influenza virus infection.
- antioxidants selected from the group consisting of Vitamin A, Vitamin E, Vitamin K, Copper (as cupric oxide), Zinc (as zinc oxide), Iron (as ferrous salt), Selenium (sodium selenate), beta-carotene, polyphenol, catechin, quercetin, eriodictyol, carnosic acid, carnosol, rosmarrinic acid, caffeic acid, coumaric acid, cinnamic acid, Coenzyme Q10, Probucol, astaxanthin, lycopene, alpha-lipoate, and urate,or pharmaceutically acceptable salt of any such antioxidant; and (c) a pharmaceutically acceptable carrier, said composition useful in preventing or treating of influenza virus infection.
- Another embodiment of the present invention relates to the method of treating influenza virus infection, or preventing infection by influenza virus, by administering to a patient in need of such treatment a pharmaceutical composition comprising
- Another embodiment of the present invention relates to the method of treating influenza virus infection, or preventing infection by influenza virus, by administering to a patient in need of such treatment a pharmaceutical composition comprising
- Another embodiment of the present invention relates to the method of treating influenza virus infection, or preventing infection by influenza virus, by administering to a patient in need of such treatment a pharmaceutical composition comprising
- N-acetyl-L-cysteine or pharmaceutically acceptable salt thereof;
- one or more antioxidants selected from the group consisting of Vitamin A, Vitamin E, Vitamin K, Copper (as cupric oxide), Zinc (as zinc oxide), Iron (as ferrous salt), Selenium (sodium selenate), beta-carotene, polyphenol, catechin, quercetin, eriodictyol, carnosic acid, carnosol, rosmarrinic acid, caffeic acid, coumaric acid, cinnamic acid, Coenzyme Q10, Probucol, astaxanthin, lycopene, alpha-lipoate, and urate, or pharmaceutically acceptable salt of any such antioxidant; and (c) a pharmaceutically acceptable carrier.
- the pharmaceutical compositions are administered as drinking solutions.
- compositions of the present invention when exogenously added at 10 to 30 mM, decreased infectivity and active influenza viral particle production at low multiplicity of infection in Madin- Darby canine kidney (MDCK) cells and normal human small airway epithelial cells.
- MDCK Madin- Darby canine kidney
- the compositions of the present invention protected when added after viral adherence; they did not protect when added only before or during viral adherence. They did not block synthesis of viral proteins or apoptosis in infected cells and did not protect against loss of the compositions of the present invention in infected cells.
- the protection against influenza infection by addition of the compositions of the present invention probably occurred by interrupting protease cleavage of the viral HA protein after particles were released.
- influenza viral particles are released from the apical surface of the epithelial cells so that supply of these compositions at relevant concentrations to the apical surface of the nasal, oral and upper respiratory epithelia can have the same effect by inhibiting protease activation of influenza virus.
- compositions of the present invention decrease infection by influenza virus.
- this invention concerns the direct use of these compositions to decrease infection and reduce production of infectious viral particles in various cell types including human airway epithelia which are a primary site of initial infection in vivo.
- preparation of these compositions for direct delivery to the oral, nasal and respiratory epithelia such as lozenge, oral rinse or nasal spray, can be used to prevent influenza infection.
- Other thiols and antioxidants can also have this effect and those compositions in combination with other thiols or antioxidants can have an increased effect.
- Such preparations are expected to be useful for reduction in risk of infection in humans and in veterinary or domestic animals.
- Preparations for supply of these compositions directly to oral, nasal and airway epithelia may also protect against other viral infections (e.g., common cold).
- vaginal or rectal suppositories, salves or other preparations for direct supply of the compositions of the present invention to epithelial surfaces could reduce viral infections at other sites.
- Glutathione abbreviated GSH, and it is also commonly named as the peptide analog gamma-L-Glu-L-Cys-Gly.
- the pharmaceutically-acceptable salts of the compounds include the conventional non-toxic salts or the quaternary ammonium salts which are formed, e.g., from inorganic or organic acids or bases.
- acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2- hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-napthalensulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tos
- Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
- the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, didbutyl; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.
- Other pharmaceutically acceptable salts include the sulfate salt ethanolate and sulfate salts. Glutathione is synthesized by the method of Ozawa, Y. et al., Bull.
- glutathione is isolated from yeast by the method of Bloch, K. et al, Methods in Enzymology 3, 603 (1957).
- Glutathione disulfide (GSSG) is synthesized by the method of Bitny- Szlachto et al., Acta Biochim. Pol. 17, 175 (1970). Ascorbate-2-phosphate is synthesized by the methods of U.S. Patent
- N-Acetyl-L-cysteine is synthesized by the methods of Smith, J. Org. Chem.26, 820 (1961), and of U.S. Patent 3,184,505, herein incorporated by reference for these purposes.
- compositions of the present invention may be administered orally, by inhalation spray, or rectally, in dosage unit formulations containing conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles.
- a method of treating and a pharmaceutical composition for treating influenza virus infection and prevention of influenza virus infection involves administering to a patient in need of such treatment a pharmaceutical carrier and a therapeutically effective amount of any composition of the present invention, or a pharmaceutically acceptable salt thereof.
- compositions may be in the form of orally- administrable suspensions, drinking solutions or tablets; nasal sprays; or olegenous suspensions or suppositories.
- compositions of the present invention are prepared according to techniques well-known in the art of pharmaceutical formulation and may contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners/flavoring agents known in the art.
- these compositions may contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art.
- Components in the formulation of a mouthwash or rinse include antimicrobials, surfactants, cosurfactants, oils, water and other additives such as sweeteners/flavoring agents known in the art.
- the composition When administered by a drinking solution, the composition comprises one or more of the compounds of the present invention, dissolved in water, with appropriate pH adjustment, and with carrier.
- the compound present may range in concentration between about 10 mM and about 200mM, preferably about 50 mM.
- the compound may be dissolved in distilled water, tap water, spring water, and the like.
- the pH is typically adjusted to between about 4.0 and 6.5, preferably about 6.0.
- Sweeteners may be added, e.g., 1% (w/v) sucrose.
- compositions When administered by nasal aerosol or inhalation, these compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubihzing or dispersing agents known in the art. See, for example, Ansel, H.C. et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, Sixth Ed. (1995). Preferably these compositions and formulations are prepared with suitable nontoxic pharmaceutically acceptable ingredients.
- nasal dosage forms generally contain large amounts of water in addition to the active ingredient. Minor amounts of other ingredients such as pH adjusters, emulsifiers or dispersing agents, preservatives, surfactants, jelling agents, or buffering and other stabilizing and solubilizing agents may also be present.
- the nasal dosage form should be isotonic with nasal secretions. For drinking solutions, sweeteners such as sucrose are preferable.
- the formulations of this invention may be varied to include; (1) other acids and bases to adjust the pH; (2) other tonicity imparting agents such as sorbitol, glycerin and dextrose; (3) other antimicrobial preservatives such as other parahydroxy benzoic acid esters, sorbate, benzoate, propionate, chlorbutanol, phenylethyl alcohol, benzalkonium chloride, and mercurials; (4) other viscosity imparting agents such as sodium carboxymethylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, polyvinyl alcohol and other gums; (5) suitable absorption enhancers; (6) stabilizing agents such as antioxidants, like bisulfite and ascorbate, metal chelating agents such as sodium edetate and drug solubility enhancers such as polyethylene glycols.
- the above nasal formulations can be administers as drops, sprays, aerosols or by any other intranasal dosage form.
- the delivery system can be a unit dose delivery system.
- the volume of solution or suspension delivered per dose can be anywhere from 5 to 400 microliters, and preferably 50 to 150 microliters. Delivery systems for these various dosage forms can be dropper bottles, plastic squeeze units, atomizers, nebulizers or pharmaceutical aerosols in either unit dose or multiple dose packages. Lozenges can be prepared according to U.S. Patent No. 3,439,089, herein incorporated by reference for these purposes.
- compositions When rectally administered in the form of suppositories, these compositions may be prepared by mixing the drug with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquidity and/or dissolve in the rectal cavity to release the drug.
- a suitable non-irritating excipient such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquidity and/or dissolve in the rectal cavity to release the drug.
- Dosage levels of the order of 25 mg/day to 10 g/day are useful in the treatment or prevention of the above-indicated conditions.
- such dosages are administered to each patient by either nasal spray or by oral lozenge.
- the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific salt or other form employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
- the present invention is also directed to compositions of the present invention with one or more antioxidants.
- glutathione and glutathione disulfide, or any other composition of the present invention may be effectively administered, whether at periods of pre-exposure or post-exposure or both, in combination with effective amounts of one or more of the antioxidants listed below:
- Vitamin A Vitamin E,
- Zinc Zinc oxide
- Beta-carotene polyphenols, flavinoids, including flavanols, such as catechin or quercetin, and flavanones such as eriodictyol, Diterpenoids, such as carnosic acid, or carnosol, Phenolic acids, e.g., rosmarrinic acid, caffeic acid, coumaric acid, or cinnamic acids,
- Carotenoids such as astaxanthin or lycopene
- Glutathione was synthesized by the method of Ozawa, Y. et al, Bull. Chem. Soc. Jpn. 53: 2592 (1980), herein incorporated by reference for these purposes.
- N-formyl-L-2-amino-4-cyanobutyric acid ethyl ester is condensed with ethyl L-cysteinylglycinate to give (4R)-2-[(3S)-3-elthoxycarbonyl- 3-(formylamino) propyl]-4-(ethoxycarbonylmethylcarbamoyl)-2-thiazoline.
- ISOLATION OF GLUTATHIONE FROM YEAST GSH is precipitated out of a yeast extract with cadmium chloride by the method of Bloch, K et al, Methods in Enzymology 3_, 603 (1957), herein incorporated by reference for these purposes.
- To an aliquot of yeast extract is added an equal weight of 10% TCA.
- the residue obtained by centrifugation is extracted twice more with half the original volume of TCA.
- To the combined extracts is added an amount of CdCl 2 solution equal to one-fourth the volume of the extracts.
- the solution is brought to pH 5 by addition of 10 M NaOH and then adjusted to pH 6.5 with bicarbonate.
- the precipitated Cd complex is kept at 0°C for 1 hour and then washed twice with ice-cold distilled water.
- the precipitate is dissolved in a minimum of 2 N H 2 SO 4 and then 3 ml of 0.5 N H 2 SO 4 is added for each 10 mg of GSH expected.
- the solution is filtered if necessary and the amount of GSH present determined in an aliquot.
- the solution is warmed to 40°C, and Cu 2 O suspension containing 2.5 mg of Cu 2 O for each 10 mg of GSH is added dropwise with gentle shaking.
- the precipitate is left at 0°C for several hours, separated by centrifugation, and washed successively two times with 0.5 N H 2 SO 4 , three times with distilled water, and two times with methanol.
- cuprous mercaptide If the cuprous mercaptide is discolored, it may be redissolved by the addition of an excess of Cu 2 O suspension in 0.5 N H 2 SO 4 . After filtration, the mercaptide reprecipitates on aerating the solution. For isolation of the free tripeptide the cuprous mercaptide of GSH is decomposed in aqueous suspension by H 2 , and the solution, after removal of copper sulfide, is brought to dryness by lyophilization.
- MDCK Madin-Darby canine kidney
- MDCK cells are cultured in 100 mm dishes until 80% confluent. Cells were washed with phosphate-buffered saline and inoculated with Influenza A/WSN strain at a multiplicity of infection of 0.05-0.1 plaque-forming units/cell in serum-free DMEM medium for 2 hours. Cells were washed with phosphate- buffered saline and supplied with DMEM + 2% FBS without or with GSH (0.1 -30 mM). At 48 hours post infection, 100 ⁇ l supermatant from each dish was assayed for virus HA titer. Results showed an increasing protection against virus production over the range of 0.1 mM to 30 mM GSH. Decreased virus production was 30% at 1 mM, 60% at 5 mM and 90% at 30 mM GSH. These concentrations of GSH were not toxic to the cells.
- GSH does not interfere with virus adherence or incorporation into cells.
- added GSH decreased HA titer at 48 h by 85%.
- GSH inhibits production of virus by cells so that the risk of spread of infection to other cells is decreased. In this way, GSH is suitable for preventing an individual from developing influenza.
- GSH inhibited virus production while allowing elimination of virus infected cells.
- GSH was found to have no effect on elimination of infected cells by apoptosis following influenza infection of MDCK cells. Almost 100% of virus infected cells showed signs of apoptosis at 48 h and this was unaffected by GSH up to 30 mM. GSH alone did not cause apoptosis. Thus, the normal process of apoptosis can eliminate infected cells and decreases the chance of spread of the virus because the GSH blocks virus production without interfering with apoptosis.
- EXAMPLE 7 Increased cellular GSH was not necessary for added GSH to protect against virus infection.
- GSH was measured in MDCK cells after infection with influenza virus either without or with 10 mM GSH. The results showed that treatment with GSH did not increase cellular GSH in the absence of virus and did not prevent the loss of GSH in the virus-infected cells. The presence of virus had no apparent affect on loss of GSH from the medium. Thus, the effects of GSH on virus infection were probably not due to effects on intracellular GSH pools, suggesting a novel mechanism of protection.
- GSSG is synthesized by the methods of Bitny-Szlachto et al., Acta Biochim. Pol. 17, 175(1970). In this procedure, GSSG is prepared by aeration of GSH in buffer at pH 8 in the presence of catalytic amounts of FeSO 4 , until negative reaction with nitroprusside occurs. Then the solution is treated with charcoal, adjusted to pH 6, concentrated under reduced pressure, and GSSG is precipitated out with ethanol.
- Glutathione disulfide protected against influenza infection by inhibiting virus production.
- MDCK cells were cultured in 100 mm dishes until 80% confluent. Cells were washed with phosphate-buffered saline and inoculated with Influenza A/WSN strain at a multiplicity of infection of 0.05-0.1 plaque-forming units/cell in serum-free DMEM medium for 2 hours. Cells were washed with phosphate- buffered saline and supplied with DMEM + 2% FBS without or with GSSG. At 48 hours post infection, 100 ⁇ l supernatant from each dish was assayed for virus HA titer. Results showed that 10 mM GSSG gave 33% and 50% inhibition of virus production at 48 and 72 h, respectively. 30 mM GSSG gave 33% and 75% inhibition of virus production at 48 and 72 h, respectively. GSSG was not toxic to cells at these concentrations. Thus, GSSG protects against virus infection by inhibiting virus production.
- Ascorbate-2-phosphate (1) also known as ascorbate-2'-phosphate, is chemically synthesized by the method of Sekine, M. et al., J. Org. Chem.4H_, 3453 (1982).
- Ascorbate-2-phosphate prevented infectious influenza virus production.
- ascorbate-2-phosphate instead of GSH showed that 10 or 30 mM ascorbate-2-phosphate provided protection against virus titer and infectious particle production.
- MDCK cells were cultured in 100 mm dishes until 80%) confluent. Cells were washed with phosphate-buffered saline and inoculated with Influenza A/WSN strain at a multiplicity of infection of 0.05-0.1 plaque- forming units/cell in serum-free DMEM medium for 2 hours. Cells were washed with phosphate-buffered saline and supplied with DMEM + 2% FBS without or with ascorbate-2-phosphate.
- Ascorbate-2-phosphate plus GSH provided greater protection than either alone.
- N-Acetyl-L-cysteine is synthesized by the methods of Smith, J.Org. Chem.26, 820 (1961). Twenty grams of cystine are dissolved in 200 ml of water containing 12 g of sodium hydroxide, and 40 ml of acetic anhydride is added dropwise with stirring and cooling in an ice bath over a period of 30 minutes. The solution is allowed to stand at room temperature 1 hr, then heated to 55°C and zinc dust added. The solution is stirred for 15 minutes, cooled, and centrifuged to remove unchanged zinc. To a portion of the centrifugate 1 M lead acetate is added. The mercaptide is centrifuged, washed, and decomposed with hydrogen sulfide.
- the lead sulfide is removed by filtration and the filtrate lyophilized. Further purification is accomplished by dissolving in isopropyl alcohol followed by precipitation with dry ether, and repeating this procedure up to three times. See also U.S. Patent 3,184,505, herein incorporated by reference for these purposes.
- N-Acetyl-L-cysteine protected against influenza infection by inhibiting virus production.
- MDCK cells were cultured in 100 mm dishes until 80% confluent. Cells were washed with phosphate-buffered saline and inoculated with Influenza A/WSN strain at a multiplicity of infection of 0.05-0.1 plaque-forming units/cell in serum-free DMEM medium for 2 hours. Cells were washed with phosphate- buffered saline and supplied with DMEM + 2% FBS without or with NAC. At 48 hours post infection, 100 ⁇ l supermatant from each dish was assayed for virus HA titer. Results showed that 10 mM NAC gave 50% and 62% inhibition of virus production at 24 and 48 h., respectively. 30 mM NAC gave 75% and 95% inhibition of virus production at 24 and 48 h., respectively. NAC was not toxic to cells at these concentrations. Thus, NAC protects against virus infection by inhibiting virus production.
- a nasal spray containing glutathione or GSSG was prepared by adding 3 mg of glutathione or GSSG per milliliter of saline (0.9%) NaCl, w/v in water).
- a nasal spray is prepared, containing
- a nasal spray is prepared, containing GSSG 1.0 g
- the sugar is dissolved in 5.5 liters of water, and the glucose-containing corn syrup is added and mixed well. At this point, any desired dye may be added to impart the required color. The dye must be dissolved thoroughly.
- the above mixture is placed in a steamjacketed kettle which is heated to 125° C from which it is pumped into a storage vessel that feeds a continuous cooker.
- a steam vacuum ejector As the syrup passes through a coil in the cooker, it reaches a temperature of 125-150° C and is then fed into a receiving kettle maintained at 28- 29 inches of vacuum by means of a steam vacuum ejector for a period of about 6-7 minutes. During this period water is removed until it is reduced to about 1% or less and a suitable molten candy base is formed. The candy base then is permitted to cool slowly.
- the medicament, citric acid and imitation flavor in powdered form are added to the polyethylene glycol and the mixture then fluidized by heating at about 90° C.
- the hot fluid mixture is rapidly added to the molten candy base (the temperature of which has been reduced to about 100° C or slightly below) with adequate mixing.
- the total mass then is kneaded thoroughly and subsequently transferred to a spinning machine which extrudes it into lozenge forming dies.
- the medicated molten candy mass is poured onto cooling tables where it solidifies to a semi-solid mass which then may be formed into any desired shape for dispensing a unit dosage of the medicament.
- Medicament Mixture Polyethylene glycol (6,000 m.w.) .. kg 2.75
- the sugar is dissolved in 5.5 liters of water, and the glucose-containing corn syrup is added and mixed well. At this point, any desired dye may be added to impart the required color. The dye must be dissolved thoroughly.
- the above mixture is placed in a steamjacketed kettle which is heated to 125° C from which it is pumped into a storage vessel that feeds a continuous cooker.
- a steam vacuum ejector As the syrup passes through a coil in the cooker, it reaches a temperature of 125-150° C and is then fed into a receiving kettle maintained at 28- 29 inches of vacuum by means of a steam vacuum ejector for a period of about 6-7 minutes. During this period water is removed until it is reduced to about 1% or less and a suitable molten candy base is formed. The candy base then is permitted to cool slowly.
- the medicament, citric acid and imitation flavor in powdered form are added to the polyethylene glycol and the mixture then fluidized by heating at about 90° C.
- the hot fluid mixture is rapidly added to the molten candy base (the temperature of which has been reduced to about 100° C or slightly below) with adequate mixing.
- the total mass then is kneaded thoroughly and subsequently transferred to a spinning machine which extrudes it into lozenge forming dies.
- the medicated molten candy mass is poured onto cooling tables where it solidifies to a semi-solid mass which then may be formed into any desired shape for dispensing a unit dosage of the medicament.
- a nasal spray containing ascorbate-2 -phosphate was prepared by adding 3 mg of glutathione per milliliter of saline (0.9% NaCl, w/v in water).
- a nasal spray is prepared, containing
- the sugar is dissolved in 5 5 liters of water, and the glucose-containing corn syrup is added and mixed well At this point, any desired dye may be added to impart the required color
- the dye must be dissolved thoroughly
- the above mixture is placed in a steamjacketed kettle which is heated to 125° C from which it is pumped into a storage vessel that feeds a contmuous cooker
- the syrup passes through a coil in the cooker, it reaches a temperature of 125-150° C and is then fed into a receiving kettle maintained at 28- 29 inches of vacuum by means of a steam vacuum ejector for a period of about 6-7 minutes During this period water is removed until it is reduced to about 1% or less and a suitable molten candy base is formed
- the candy base then is permitted to cool slowly
- the medicament, citric acid and imitation flavor in powdered form are added to the polyethylene glycol and the mixture then fluidized by heating at about 90° C
- the hot fluid mixture is rapidly added to the molten candy base (the temperature of which has been reduced to about 100° C or slightly below) with adequate mixing
- the total mass then is kneaded thoroughly and subsequently transferred to a spinning machine which extrudes it into lozenge forming dies
- the medicated molten candy mass is poured onto cooling tables where it solidifies to a semi-solid mass which then may be formed into any desired shape for dispensing a unit dosage of the medicament.
- a nasal spray containing N-acetyl-L-Cysteine was prepared by adding 3 mg of N-acetyl-L-Cysteine per milliliter of saline (0.9%) NaCl, w/v in water).
- a nasal spray is prepared, containing
- Medicament Mixture Polyethylene glycol (6,000 m.w.) .. kg 2.75
- the sugar is dissolved in 5.5 liters of water, and the glucose-containing corn syrup is added and mixed well. At this point, any desired dye may be added to impart the required color. The dye must be dissolved thoroughly.
- the above mixture is placed in a steamjacketed kettle which is heated to 125° C from which it is pumped into a storage vessel that feeds a continuous cooker.
- a steam vacuum ej ector As the syrup passes through a coil in the cooker, it reaches a temperature of 125-150° C and is then fed into a receiving kettle maintained at 28- 29 inches of vacuum by means of a steam vacuum ej ector for a period of about 6-7 minutes. During this period water is removed until it is reduced to about 1% or less and a suitable molten candy base is formed. The candy base then is permitted to cool slowly.
- the medicament, citric acid and imitation flavor in powdered form are added to the polyethylene glycol and the mixture then fluidized by heating at about 90° C.
- the hot fluid mixture is rapidly added to the molten candy base (the temperature of which has been reduced to about 100° C or slightly below) with adequate mixing.
- the total mass then is kneaded thoroughly and subsequently transferred to a spinning machine which extrudes it into lozenge forming dies.
- the medicated molten candy mass is poured onto cooling tables where it solidifies to a semi-solid mass which then may be formed into any desired shape for dispensing a unit dosage of the medicament.
- a nasal spray containing glutathione and N-acetyl-L-Cysteine was prepared by adding 1.0 mg of glutathione and 2.0 mg N-acetyl-L-Cysteine, each per milliliter of saline (0.9% NaCl, w/v in water).
- a nasal spray is prepared, containing
- a nasal spray is prepared containing
- the sugar is dissolved in 5 5 liters of water, and the glucose-containing corn syrup is added and mixed well At this point, any desired dye may be added to impart the required color The dye must be dissolved thoroughly
- the above mixture is placed in a steamjacketed kettle which is heated to 125°C, from which it is pumped into a storage vessel that feeds a continuous cooker
- a steam vacuum ejector for a period of about 6-7 mmutes Durmg this period water is removed until it is reduced to about 1% or less and a suitable molten candy base is formed
- the candy base then is permitted to cool slowly
- the medicament, citric acid and imitation flavor in powered form are added to the polyethylene glycol and the mixture then fluidized by heating at about 90°C
- the hot fluid mixture is rapidly added to the molten candy base (the temperature of which has been reduced to about 100°C, or slightly below) with adequate mixing.
- the total mass then is kneaded thoroughly and subsequently transferred to a spinning machine which extrudes it into lozenge forming dies.
- the medicated molten candy mass is poured onto cooling tables where it solidifies to a semi-solid mass, which then may be formed into any desired shape for dispensing a unit dosage of the medicament.
- the sugar is dissolved in 5.5 liters of water, and the glucose-containing corn syrup is added and mixed well. At this point, any desired dye may be added to impart the required color. The dye must be dissolved thoroughly.
- the above mixture is placed in a steamjacketed kettle which is heated to 125°C, from which it is pumped into a storage vessel that feeds a continuous cooker.
- a steam vacuum ejector As the syrup passes through a coil in the cooker, it reaches a temperature of 125-150°C, and is then fed into a receiving kettle maintained at 28- 29 inches of vacuum by means of a steam vacuum ejector for a period of about 6-7 minutes. During this period water is removed until it is reduced to about 1% or less and a suitable molten candy base is formed. The candy base then is permitted to cool slowly.
- the medicament, citric acid and imitation flavor in powered form are added to the polyethylene glycol and the mixture then fluidized by heating at about 90°C.
- the hot fluid mixture is rapidly added to the molten candy base (the temperature of which has been reduced to about 100°C, or slightly below) with adequate mixing.
- the total mass then is kneaded thoroughly and subsequently transferred to a spinning machine which extrudes it into lozenge forming dies.
- the medicated molten candy mass is poured onto cooling tables where it solidifies to a semi-solid mass, which then may be formed into any desired shape for dispensing a unit dosage of the medicament.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP53111198A JP4578578B2 (en) | 1997-01-13 | 1998-01-12 | Compounds for the treatment of influenza infection and combinations thereof |
AU59109/98A AU5910998A (en) | 1997-01-13 | 1998-01-12 | Compounds and their combinations for the treatment of influenza infection |
AT98902446T ATE444760T1 (en) | 1997-01-13 | 1998-01-12 | GLUTATHIONE FOR THE TREATMENT OF INFLUENCE INFECTIONS |
EP98902446A EP1007077B1 (en) | 1997-01-13 | 1998-01-12 | Glutathione for the treatment of influenza infection |
DE69841217T DE69841217D1 (en) | 1997-01-13 | 1998-01-12 | GLUTATHION FOR THE TREATMENT OF INFLUENZA INFECTIONS |
CA2277911A CA2277911C (en) | 1997-01-13 | 1998-01-12 | Compounds and their combinations for the treatment of influenza infection |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3508897P | 1997-01-13 | 1997-01-13 | |
US3449697P | 1997-01-13 | 1997-01-13 | |
US3508797P | 1997-01-13 | 1997-01-13 | |
US3541797P | 1997-01-13 | 1997-01-13 | |
US60/035,088 | 1997-01-13 | ||
US60/034,496 | 1997-01-13 | ||
US60/035,087 | 1997-01-13 | ||
US60/035,417 | 1997-01-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998030228A1 true WO1998030228A1 (en) | 1998-07-16 |
WO1998030228B1 WO1998030228B1 (en) | 1998-09-03 |
Family
ID=27488222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/000380 WO1998030228A1 (en) | 1997-01-13 | 1998-01-12 | Compounds and their combinations for the treatment of influenza infection |
Country Status (8)
Country | Link |
---|---|
US (2) | US6013632A (en) |
EP (1) | EP1007077B1 (en) |
JP (1) | JP4578578B2 (en) |
AT (1) | ATE444760T1 (en) |
AU (1) | AU5910998A (en) |
CA (1) | CA2277911C (en) |
DE (1) | DE69841217D1 (en) |
WO (1) | WO1998030228A1 (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999027941A1 (en) * | 1997-12-01 | 1999-06-10 | Thione International, Inc. | Oral antioxidant preparation comprising selenium and reduced glutathione |
WO2000007575A2 (en) * | 1998-07-31 | 2000-02-17 | Mount Sinai Hospital | Methods and compositions for increasing insulin sensitivity |
WO2000053176A1 (en) * | 1999-03-05 | 2000-09-14 | Uni-Ci S.R.L. | Pharmaceutic, dietetic and cosmetic compositions based on thioctic acid and cysteine |
EP1145719A2 (en) * | 2000-03-10 | 2001-10-17 | Pfizer Products Inc. | Use a ferrous salt for inhibiting oxidative degradation of pharmaceutical formulations |
WO2002009699A2 (en) * | 2000-07-28 | 2002-02-07 | Immupharm Aps | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
WO2002034262A1 (en) * | 2000-10-25 | 2002-05-02 | Giuliani S.P.A. | Combination of catechin and quercetin for pharmaceutical or dietary use |
EP1238644A1 (en) * | 1999-12-15 | 2002-09-11 | Kyowa Hakko Kogyo Co., Ltd. | Stabilizers for l-ascorbic acid-2-sodium phosphate |
WO2002078717A2 (en) * | 2001-03-28 | 2002-10-10 | Societe Des Produits Nestle S.A. | Compositions and methods for reducing rna virus pathogenicity |
WO2002097072A2 (en) * | 2001-05-30 | 2002-12-05 | Saechsisches Serumwerk Dresden Branch Of Smithkline Beecham Pharma Gmbh & Co. Kg | Influenza vaccine composition |
ES2178589A1 (en) * | 2000-01-27 | 2002-12-16 | Goodyear Tire & Rubber | Chewing gum base stabilized with carnosic acid |
WO2003028717A1 (en) * | 2001-09-05 | 2003-04-10 | Zambon Group S.P.A. | A drugs association against influenza virus |
WO2005007640A1 (en) | 2003-07-22 | 2005-01-27 | Kyowa Hakko Kogyo Co., Ltd. | Preventive or therapeutic composition for viral infectious disease |
EP1531156A1 (en) * | 2003-11-17 | 2005-05-18 | Clariant International Ltd. | Method for synthesis of silylated ascorbic acid derivatives |
US7517540B2 (en) | 1999-06-01 | 2009-04-14 | Ocean Spray Cranberries, Inc. | Cranberry seed oil extract and compositions containing components thereof |
WO2009128523A1 (en) | 2008-04-17 | 2009-10-22 | 味の素株式会社 | Immunostimulating agent |
DE102009003974A1 (en) * | 2009-01-07 | 2010-07-15 | Medphano Arzneimittel Gmbh | Oral high-dose vitamin K1-containing preparation, useful for increasing the resistance of the human organism against influenza infection |
US7767714B2 (en) | 2002-02-18 | 2010-08-03 | Ajinomoto Co., Inc. | Method of preventing infectious diseases |
ITMI20101459A1 (en) * | 2010-08-02 | 2012-02-03 | Raffaele Ansovini | COMPOSITION INCLUDING GLUTATION AND REDUCTASE AND OXIDIZED GLUTATION |
ITNA20100054A1 (en) * | 2010-11-03 | 2012-05-04 | Stewart Italia Srl | NAC BASED PHARMACEUTICAL PREPARATION IN HYPERTONIC SOLUTION FOR THE TREATMENT OF RINOFARINGEAL AFFECTIONS |
WO2012136851A1 (en) * | 2011-04-08 | 2012-10-11 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for inhibiting influenza viruses replication |
US20140302171A1 (en) * | 2011-10-12 | 2014-10-09 | For Days Co., Ltd | Cysteine Peptide-Containing Health Drink |
FR3058640A1 (en) * | 2016-11-14 | 2018-05-18 | Robert Vachy | COMPOUNDS FOR THEIR USE IN THE TREATMENT OF INFLUENZA |
WO2019098877A1 (en) | 2017-11-17 | 2019-05-23 | Obschestvo S Ogranichennoy Otvetstvennostju "Iva Farm" | Pharmaceutical composition comprising glutatione disulfide and glutathione disulfide s-oxide |
WO2021217221A1 (en) * | 2020-05-01 | 2021-11-04 | MUCPharm Pty Ltd | Preventing and treating viral infections |
WO2021236958A1 (en) * | 2020-05-22 | 2021-11-25 | Auro Pharmaceuticals, Inc. | Compositions and methods of treatment with glutathione |
WO2022011305A3 (en) * | 2020-07-09 | 2022-02-10 | Beyond Barriers Therapeutics, Inc. | Intranasal administration of an antioxidant compound for treating coronavirus infection |
US11351262B2 (en) | 2011-06-16 | 2022-06-07 | Nayan Patel | Method for stabilization and delivery of therapeutic molecules |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8507018B2 (en) * | 1998-03-12 | 2013-08-13 | Mars, Incorporated | Products containing polyphenol(s) and L-arginine and methods of use thereof |
US6231889B1 (en) * | 1998-09-21 | 2001-05-15 | Chronorx, Llc | Unit dosage forms for the treatment of herpes simplex |
RU2144374C1 (en) * | 1998-11-23 | 2000-01-20 | Закрытое акционерное общество "ВАМ" | Method of preparing of oxidized glutathione-cis- diaminodichloroplatinum complex and pharmaceutical compositions based on this complex for controlling metabolism, proliferation, and differentiation, and mechanisms of apoptosis of normal and transformated cells |
US20070142267A1 (en) * | 1998-11-23 | 2007-06-21 | Novelos Therapeutics, Inc. | Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells |
US6187332B1 (en) * | 1999-06-14 | 2001-02-13 | Wisconsin Alumni Research Foundation | Acidic buffered nasal spray |
GB9923176D0 (en) * | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
US20040234457A1 (en) * | 1999-10-19 | 2004-11-25 | The Procter & Gamble Company | Methods of preventing and treating SARS using low pH respiratory tract compositions |
US20040033260A1 (en) * | 1999-10-19 | 2004-02-19 | The Procter & Gamble Company | Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc |
JP3988014B2 (en) * | 2000-02-02 | 2007-10-10 | 味の素株式会社 | Antiviral agent |
SE0003907D0 (en) * | 2000-10-27 | 2000-10-27 | Swe Dencare | Composition for the elimination of tartar from the mouth |
US7776315B2 (en) * | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
ES2254523T3 (en) * | 2000-11-22 | 2006-06-16 | Rxkinetix, Inc. | TREATMENT OF MUCOSITIS. |
US20100310477A1 (en) * | 2000-11-28 | 2010-12-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg. | Pharmaceutical compositions based on anticholingerics and additional active ingredients |
AU2002240115B2 (en) * | 2001-01-24 | 2007-01-04 | Discus Dental, Llc. | Topical oral care compositions |
WO2002087593A1 (en) * | 2001-04-25 | 2002-11-07 | Cobalz Limited | A method for treating or preventing a functional vitamin b12 deficiency in an individual and to medical compositions for use in said method |
US6929800B2 (en) * | 2001-08-06 | 2005-08-16 | Abdul Rasoul Salman | Nasal passage cleaning composition |
CA2357053A1 (en) * | 2001-09-04 | 2003-03-04 | Unknown | Effectiveness of a combination of antioxidant substances for the treatment of alzheimer's disease |
US20040022873A1 (en) * | 2001-11-09 | 2004-02-05 | Guilford F. Timothy | Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as anthrax, smallpox or radiation and for vaccination prophylaxis, and use in combination with DHEA for the treatment of smallpox and other viruses |
US8679462B2 (en) * | 2002-04-11 | 2014-03-25 | Saeed Rezakhany | Methods of preventing respiratory infections |
DE10300222A1 (en) * | 2003-01-03 | 2004-07-15 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Use of active substances for the prophylaxis and / or therapy of viral diseases |
JP2005104852A (en) * | 2003-09-29 | 2005-04-21 | Kyowa Hakko Kogyo Co Ltd | Prophylactic or treating composition for morbillivirus infectious disease |
WO2007000662A2 (en) * | 2005-02-03 | 2007-01-04 | Taro Pharmaceuticals U.S.A., Inc. | Novel propofol composition comprising ascorbic acid or pharmaceutically acceptable salts thereof |
EP1871883A1 (en) * | 2005-03-02 | 2008-01-02 | Metanomics GmbH | Process for the production of fine chemicals |
EP1868572A4 (en) * | 2005-03-29 | 2011-03-09 | F Timothy Guilford | Administration of glutathione (reduced) via intravenous or encapsulated in liposome for treatment of tnf-alpha effects and elu-like viral symptoms |
EP1877422A4 (en) * | 2005-04-26 | 2011-08-10 | Univ South Florida | Green tea polyphenol alpha secretase enhancers and methods of use |
US20070009443A1 (en) * | 2005-07-05 | 2007-01-11 | Hensley Charles B | Method for inhibiting occupation by rhinovirus of cell in the nasal membrane |
US20070098790A1 (en) * | 2005-10-31 | 2007-05-03 | David Jiang | Nutritional supplement for the enhancement of the health of the liver |
CA2635603C (en) * | 2005-11-30 | 2016-01-19 | Endo Pharmaceuticals Inc. | Treatment of xerostomia |
US20080014277A1 (en) * | 2006-07-14 | 2008-01-17 | Insight Pharmaceuticals Llc | Reduced-odor thiol compositions |
US20080275030A1 (en) * | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
JP4300370B2 (en) | 2007-03-13 | 2009-07-22 | 春三 小林 | Epithelial improving agent |
EP2219602A1 (en) * | 2007-11-15 | 2010-08-25 | Amgen, Inc | Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration |
CN102413824A (en) | 2009-04-28 | 2012-04-11 | Wm.雷格利Jr.公司 | Oral compositions for skin benefits |
US20110064828A1 (en) * | 2009-09-11 | 2011-03-17 | Novelos Therapeutics, Incorporated | Treatment of metastatic tumors and other conditions |
AU2010337947B2 (en) * | 2009-12-30 | 2015-11-05 | Bagi Research Limited | Materials and methods for prevention and treatment of viral infections |
US8916179B2 (en) | 2011-10-25 | 2014-12-23 | T.F.H. Publications, Inc. | Ascophyllum nodosum animal chews |
KR101725101B1 (en) * | 2015-03-20 | 2017-04-11 | 주식회사 비에이치랩 | Compositions and Methods for skin whitening comprising glutathione |
WO2018204394A1 (en) * | 2017-05-02 | 2018-11-08 | The Proimmune Company L.L.C. | Compositions and methods for the treatment of zika viral diseases |
JPWO2021235494A1 (en) * | 2020-05-20 | 2021-11-25 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3184505A (en) | 1962-06-18 | 1965-05-18 | Mead Johnson & Co | Process for the n-monoacylation of cysteine |
US3439089A (en) | 1968-03-27 | 1969-04-15 | Merck & Co Inc | Medicated hard candy |
US5212079A (en) | 1987-10-08 | 1993-05-18 | Kyowa Hakko Kogyo Kabushiki Kaisha | Process for the preparation of ascorbic acid-2-phosphate |
US5250425A (en) | 1990-06-21 | 1993-10-05 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing ascorbic acid-2-phosphate |
EP0502054B1 (en) * | 1989-11-24 | 1995-03-22 | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE | An aerosol preparation of glutathione and a method for augmenting glutathione level in lungs |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1125675A (en) * | 1966-02-10 | 1968-08-28 | Kyowa Hakko Kogyo Kk | Stable ascorbic acid composition and process for preparing the same |
DE2509531A1 (en) * | 1975-03-05 | 1976-09-16 | Thomae Gmbh Dr K | ANTIVIRAL AGENT |
RO79426B1 (en) * | 1982-02-23 | 1984-07-30 | Romulus Constantin Dinu | Medicinal composition for treating neuroviroses |
US4867973A (en) * | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
JPS59231016A (en) * | 1983-06-13 | 1984-12-25 | Suntory Ltd | Stable vitamin c pharmaceutical preparation |
US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5091171B2 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
US4895716A (en) * | 1987-06-09 | 1990-01-23 | Biogen, Inc. | Stabilized formulations of gamma interferons |
DE3728917A1 (en) * | 1987-08-29 | 1989-03-09 | Roth Hermann J | Novel lipids containing an asymmetrically substituted disulphide bridge, processes for their preparation, and their use as medicaments |
US5541297A (en) * | 1988-04-01 | 1996-07-30 | Immunomedics, Inc. | Therapeutic conjugates of toxins and drugs |
CA1339256C (en) * | 1989-01-26 | 1997-08-12 | Wulf Droge | Treatment of diseases associated with hiv-infections |
US5011678A (en) * | 1989-02-01 | 1991-04-30 | California Biotechnology Inc. | Composition and method for administration of pharmaceutically active substances |
JP2926412B2 (en) * | 1989-05-19 | 1999-07-28 | 株式会社林原生物化学研究所 | α-Glycosyl-L-ascorbic acid, its production method and use |
US4965066A (en) * | 1989-06-06 | 1990-10-23 | E. I. Du Pont De Nemours And Company | Intranasal administration of 3,3-disubstituted indolines |
US5292773A (en) * | 1990-02-14 | 1994-03-08 | Hirsch Gerald P | Treating aids and HIV infection with methionine |
GB2243150B (en) * | 1990-03-28 | 1994-06-29 | Kobe Steel Ltd | Method for synthesizing diamond by combustion |
JPH0427356A (en) * | 1990-05-22 | 1992-01-30 | Yoshie Kurihara | Method for stabilizing taste modifying composition and taste modifying substance |
JP2749186B2 (en) * | 1990-08-16 | 1998-05-13 | ハウス食品株式会社 | Strawberry dye and strawberry dyeing method |
US5464825A (en) * | 1991-03-14 | 1995-11-07 | Cornell Research Foundation, Inc. | Raising glutathione equivalent levels using N-acyl glutathione monoesters |
US5164398A (en) * | 1991-04-01 | 1992-11-17 | Merck & Co., Inc. | Ibuprofen-antitussive combinations |
US5240694A (en) * | 1991-09-23 | 1993-08-31 | University Of Virginia | Combined antiviral and antimediator treatment of common colds |
US5554655A (en) * | 1991-09-30 | 1996-09-10 | Jess G. Thoene | Method of treating HIV infection |
DE69210737T2 (en) * | 1991-09-30 | 1996-10-02 | Transcend Therapeutics Inc | Use of L-2-oxothiazolidine-4-carboxylates for the manufacture of a medicament for the treatment of latent HIV infections |
US5492689A (en) * | 1991-11-19 | 1996-02-20 | The Center For Innovative Technology | Combined virustatic antimediator (COVAM) treatment of common colds |
EP1997894B1 (en) * | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
JPH06199697A (en) * | 1992-03-06 | 1994-07-19 | Yunie:Kk | Antiviral, antibacterial and fungicidal agent |
US5214062A (en) * | 1992-04-08 | 1993-05-25 | Clintec Nutrition Co. | Method and composition for treating immune disorders, inflammation and chronic infections |
US5430045A (en) * | 1992-04-23 | 1995-07-04 | Free Radical Sciences, Inc. | Method of reducing or preventing bone marrow hypoplasia |
AU661379B2 (en) * | 1992-04-23 | 1995-07-20 | Transcend Therapeutics, Inc | Method of reducing or preventing toxicity associated with antiretroviral therapy |
US5208249A (en) * | 1992-08-20 | 1993-05-04 | Clintec Nutrition Co. | Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate |
US5376633A (en) * | 1992-09-30 | 1994-12-27 | Lezdey; John | Method for deactivating viruses in blood component containers |
NZ256346A (en) * | 1992-10-09 | 1997-04-24 | Procter & Gamble | Medicaments containing 3-l-menthoxypropane-1,2-diol for treating cold symptoms |
US5463029A (en) * | 1992-11-23 | 1995-10-31 | Immunex Corporation | Purification of fusion proteins comprising GM-CSF and IL-3 |
AU5040493A (en) * | 1992-11-30 | 1994-06-09 | Transcend Therapeutics, Inc | Method for treating systemic inflammatory response syndrome |
AU6060694A (en) * | 1993-05-10 | 1994-11-17 | Transcend Therapeutics, Inc | Method for treating acquired immune deficiency syndrome |
US5686436A (en) * | 1993-05-13 | 1997-11-11 | Hiv Diagnostics, Inc. | Multi-faceted method to repress reproduction of latent viruses in humans and animals |
FR2708288B1 (en) * | 1993-07-26 | 1995-09-01 | Bio Merieux | Method for amplification of nucleic acids by transcription using displacement, reagents and necessary for the implementation of this method. |
US5432274A (en) * | 1993-07-28 | 1995-07-11 | National Research Council Of Canada | Redox dye and method of preparation thereof using 2-hydroxypropyl-β-cyclodextrin and 1,1'-dimethylferrocene |
DE4325547C2 (en) * | 1993-07-29 | 1997-11-27 | Max Planck Gesellschaft | Use of thiol compounds for the therapy of hepatitis-virus-induced diseases |
AU7604094A (en) * | 1993-09-07 | 1995-03-27 | Procter & Gamble Company, The | Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive |
US5516921A (en) * | 1994-01-27 | 1996-05-14 | Ariad Pharmaceuticals, Inc. | Thiono-lactone inhibitors of protein trafficking and uses therefor |
JPH0838065A (en) * | 1994-08-03 | 1996-02-13 | Nichimo Co Ltd | Antiviral agent for fish |
DE4431175A1 (en) * | 1994-09-01 | 1996-04-11 | Medico Pharma Vertriebs Gmbh | New drugs containing chelating agents |
GB9502489D0 (en) * | 1995-02-09 | 1995-03-29 | Animal Health Trust | Expression of the non-structural protein NS1 of influenza virus and detection of anti-NS1 antibody in serum |
-
1998
- 1998-01-12 JP JP53111198A patent/JP4578578B2/en not_active Expired - Lifetime
- 1998-01-12 AT AT98902446T patent/ATE444760T1/en not_active IP Right Cessation
- 1998-01-12 DE DE69841217T patent/DE69841217D1/en not_active Expired - Fee Related
- 1998-01-12 US US09/005,747 patent/US6013632A/en not_active Expired - Lifetime
- 1998-01-12 CA CA2277911A patent/CA2277911C/en not_active Expired - Lifetime
- 1998-01-12 EP EP98902446A patent/EP1007077B1/en not_active Expired - Lifetime
- 1998-01-12 AU AU59109/98A patent/AU5910998A/en not_active Abandoned
- 1998-01-12 WO PCT/US1998/000380 patent/WO1998030228A1/en active Application Filing
-
1999
- 1999-06-24 US US09/339,629 patent/US6107281A/en not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3184505A (en) | 1962-06-18 | 1965-05-18 | Mead Johnson & Co | Process for the n-monoacylation of cysteine |
US3439089A (en) | 1968-03-27 | 1969-04-15 | Merck & Co Inc | Medicated hard candy |
US5212079A (en) | 1987-10-08 | 1993-05-18 | Kyowa Hakko Kogyo Kabushiki Kaisha | Process for the preparation of ascorbic acid-2-phosphate |
EP0502054B1 (en) * | 1989-11-24 | 1995-03-22 | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE | An aerosol preparation of glutathione and a method for augmenting glutathione level in lungs |
US5250425A (en) | 1990-06-21 | 1993-10-05 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing ascorbic acid-2-phosphate |
Non-Patent Citations (11)
Title |
---|
"NUTRITION FACTS AND FICTION ABOUT VITAMIN E.", HARVARD HEALTH LETTER, BOSTON, MA, US, vol. 22., no. 01., 1 November 1996 (1996-11-01), US, pages 01 - 03., XP002912422, ISSN: 1052-1577 * |
BITNYSZLACHTO ET AL., ACTA BIOCHIM. POL., vol. 17, 1970, pages 175 |
BLOCH, K. ET AL., METHODS IN ENZYMOLOGY, vol. 1, 1957, pages 603 |
CINATL J., ET AL.: "IN VITRO INHIBITION OF HUMAN CYTOMEGALOVIRUS REPLICATION IN HUMAN FORESKIN FIBROBLASTS AND ENDOTHELIAL CELLS BY ASCORBIC ACID 2-PHOSPHATE.", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 27., 1 August 1995 (1995-08-01), NL, pages 405 - 418., XP002912420, ISSN: 0166-3542, DOI: 10.1016/0166-3542(95)00024-G * |
EAUCLAIRE S.: "PREVENTING COLDS AND FLU.", VEGETARIAN TIMES, NEW YORK, NY, US, 1 December 1996 (1996-12-01), US, pages 26 - 31., XP002912423, ISSN: 0164-8497 * |
FLORA DE S., GRASSI C., CARATI L.: "ATTENUATION OF INFLUENZA-LIKE SYMPTOMATOLOGY AND IMPROVEMENT OF CELL-MEDIATED IMMUNITY WITH LONG-TERM N-ACETYLCYSTEINE TREATMENT.", EUROPEAN RESPIRATORY JOURNAL., MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN., DK, vol. 10., 1 July 1997 (1997-07-01), DK, pages 1535 - 1541., XP002912424, ISSN: 0903-1936, DOI: 10.1183/09031936.97.10071535 * |
HENNET T., PETERHANS E., STOCKER R.: "ALTERATIONS IN ANTIOXIDANT DEFENCES IN LUNG AND LIVER OF MICE INFECTED WITH INFLUENZA A VIRUS.", JOURNAL OF GENERAL VIROLOGY., SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD., GB, vol. 73., 1 January 1992 (1992-01-01), GB, pages 39 - 46., XP002912421, ISSN: 0022-1317 * |
OZAWA, Y. ET AL., BULL. CHEM. SOC. JPN., vol. 53, 1980, pages 2592 |
SEKIN, M. ET AL., J. ORG. CHEM., vol. 47, 1982, pages 3453 |
SMITH, ORG. CHEM., vol. 26, 1961, pages 820 |
TODISCO T., ET AL.: "PROTECTIVE EFFECT OF N-ACETYLCYSTEINE ON IMMUNE SYSTEM OF ELDERLY PATIENTS IN ACUTE REPIRATORY VIRAL INFECTIONS.", ANNUAL CONGRESS. EUROPEAN RESPIRATORY SOCIETY ERS. ABSTRACTS, XX, XX, 25 September 1993 (1993-09-25), XX, pages 559 S., XP002912419 * |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU740020B2 (en) * | 1997-12-01 | 2001-10-25 | Thione International, Inc. | Oral antioxidant preparation comprising selenium and reduced glutathione |
WO1999027941A1 (en) * | 1997-12-01 | 1999-06-10 | Thione International, Inc. | Oral antioxidant preparation comprising selenium and reduced glutathione |
WO2000007575A2 (en) * | 1998-07-31 | 2000-02-17 | Mount Sinai Hospital | Methods and compositions for increasing insulin sensitivity |
WO2000007575A3 (en) * | 1998-07-31 | 2000-05-11 | Mount Sinai Hospital Corp | Methods and compositions for increasing insulin sensitivity |
US6258848B1 (en) | 1998-07-31 | 2001-07-10 | Mount Sinai Hospital | Methods and compositions for increasing insulin sensitivity |
WO2000053176A1 (en) * | 1999-03-05 | 2000-09-14 | Uni-Ci S.R.L. | Pharmaceutic, dietetic and cosmetic compositions based on thioctic acid and cysteine |
US7517540B2 (en) | 1999-06-01 | 2009-04-14 | Ocean Spray Cranberries, Inc. | Cranberry seed oil extract and compositions containing components thereof |
US8034389B2 (en) | 1999-06-01 | 2011-10-11 | Ocean Spray Cranberries, Inc. | Cranberry seed oil extract and compositions containing components thereof |
EP1238644A1 (en) * | 1999-12-15 | 2002-09-11 | Kyowa Hakko Kogyo Co., Ltd. | Stabilizers for l-ascorbic acid-2-sodium phosphate |
EP1238644A4 (en) * | 1999-12-15 | 2006-04-05 | Kyowa Hakko Kogyo Kk | Stabilizers for l-ascorbic acid-2-sodium phosphate |
ES2178589A1 (en) * | 2000-01-27 | 2002-12-16 | Goodyear Tire & Rubber | Chewing gum base stabilized with carnosic acid |
US6423351B2 (en) | 2000-03-10 | 2002-07-23 | Pfizer Inc. | Inhibiting oxidative degradation of pharmaceutical formulations |
EP1145719A3 (en) * | 2000-03-10 | 2001-11-14 | Pfizer Products Inc. | Use a ferrous salt for inhibiting oxidative degradation of pharmaceutical formulations |
EP1145719A2 (en) * | 2000-03-10 | 2001-10-17 | Pfizer Products Inc. | Use a ferrous salt for inhibiting oxidative degradation of pharmaceutical formulations |
EA008612B1 (en) * | 2000-07-28 | 2007-06-29 | Иммуфарм Апс | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
WO2002009699A3 (en) * | 2000-07-28 | 2003-01-03 | Immupharm Aps | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
US8003688B2 (en) | 2000-07-28 | 2011-08-23 | Immupharm Aps | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
WO2002009699A2 (en) * | 2000-07-28 | 2002-02-07 | Immupharm Aps | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
WO2002034262A1 (en) * | 2000-10-25 | 2002-05-02 | Giuliani S.P.A. | Combination of catechin and quercetin for pharmaceutical or dietary use |
US7956040B2 (en) | 2000-10-25 | 2011-06-07 | Giuliani International Limited | Combination of catechin and quercetin for pharmaceutical or dietary use |
WO2002078717A2 (en) * | 2001-03-28 | 2002-10-10 | Societe Des Produits Nestle S.A. | Compositions and methods for reducing rna virus pathogenicity |
WO2002078717A3 (en) * | 2001-03-28 | 2003-08-28 | Nestle Sa | Compositions and methods for reducing rna virus pathogenicity |
EP2039761A1 (en) * | 2001-05-30 | 2009-03-25 | Saechsisches Serumwerk Dresden | Influenza vaccine composition |
US7316813B2 (en) | 2001-05-30 | 2008-01-08 | Saechsisches Serumwerk Dresden Branch Of Smithkline Beecham Pharma Gmbh & Co Kg | Influenza vaccine composition |
WO2002097072A2 (en) * | 2001-05-30 | 2002-12-05 | Saechsisches Serumwerk Dresden Branch Of Smithkline Beecham Pharma Gmbh & Co. Kg | Influenza vaccine composition |
WO2002097072A3 (en) * | 2001-05-30 | 2003-04-24 | Saechsisches Serumwerk | Influenza vaccine composition |
WO2003028717A1 (en) * | 2001-09-05 | 2003-04-10 | Zambon Group S.P.A. | A drugs association against influenza virus |
US7767714B2 (en) | 2002-02-18 | 2010-08-03 | Ajinomoto Co., Inc. | Method of preventing infectious diseases |
WO2005007640A1 (en) | 2003-07-22 | 2005-01-27 | Kyowa Hakko Kogyo Co., Ltd. | Preventive or therapeutic composition for viral infectious disease |
EP1531156A1 (en) * | 2003-11-17 | 2005-05-18 | Clariant International Ltd. | Method for synthesis of silylated ascorbic acid derivatives |
WO2009128523A1 (en) | 2008-04-17 | 2009-10-22 | 味の素株式会社 | Immunostimulating agent |
US8454978B2 (en) | 2008-04-17 | 2013-06-04 | Ajinomoto Co., Inc. | Immunostimulating agent |
DE102009003974A1 (en) * | 2009-01-07 | 2010-07-15 | Medphano Arzneimittel Gmbh | Oral high-dose vitamin K1-containing preparation, useful for increasing the resistance of the human organism against influenza infection |
ITMI20101459A1 (en) * | 2010-08-02 | 2012-02-03 | Raffaele Ansovini | COMPOSITION INCLUDING GLUTATION AND REDUCTASE AND OXIDIZED GLUTATION |
WO2012017367A1 (en) * | 2010-08-02 | 2012-02-09 | Cattarini Mastelli, Giulia | Composition comprising glutathione reductase and oxidized glutathione, and therapeutic uses thereof |
US8852582B2 (en) | 2010-08-02 | 2014-10-07 | Giulia Cattarini Mastelli | Compositions comprising glutathione reductase and oxidized glutathione |
ITNA20100054A1 (en) * | 2010-11-03 | 2012-05-04 | Stewart Italia Srl | NAC BASED PHARMACEUTICAL PREPARATION IN HYPERTONIC SOLUTION FOR THE TREATMENT OF RINOFARINGEAL AFFECTIONS |
WO2012136851A1 (en) * | 2011-04-08 | 2012-10-11 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for inhibiting influenza viruses replication |
CN103648491A (en) * | 2011-04-08 | 2014-03-19 | 法国国家健康医学研究院 | Methods and pharmaceutical compositions for inhibiting influenza viruses replication |
US9168236B2 (en) | 2011-04-08 | 2015-10-27 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Methods and pharmaceutical compositions for inhibiting influenza viruses replication |
US11351262B2 (en) | 2011-06-16 | 2022-06-07 | Nayan Patel | Method for stabilization and delivery of therapeutic molecules |
US11602564B2 (en) | 2011-06-16 | 2023-03-14 | Nayan Patel | Method for stabilization and delivery of therapeutic molecules |
US20140302171A1 (en) * | 2011-10-12 | 2014-10-09 | For Days Co., Ltd | Cysteine Peptide-Containing Health Drink |
FR3058640A1 (en) * | 2016-11-14 | 2018-05-18 | Robert Vachy | COMPOUNDS FOR THEIR USE IN THE TREATMENT OF INFLUENZA |
WO2019098877A1 (en) | 2017-11-17 | 2019-05-23 | Obschestvo S Ogranichennoy Otvetstvennostju "Iva Farm" | Pharmaceutical composition comprising glutatione disulfide and glutathione disulfide s-oxide |
WO2021217221A1 (en) * | 2020-05-01 | 2021-11-04 | MUCPharm Pty Ltd | Preventing and treating viral infections |
WO2021236958A1 (en) * | 2020-05-22 | 2021-11-25 | Auro Pharmaceuticals, Inc. | Compositions and methods of treatment with glutathione |
WO2022011305A3 (en) * | 2020-07-09 | 2022-02-10 | Beyond Barriers Therapeutics, Inc. | Intranasal administration of an antioxidant compound for treating coronavirus infection |
Also Published As
Publication number | Publication date |
---|---|
US6013632A (en) | 2000-01-11 |
CA2277911A1 (en) | 1998-07-16 |
US6107281A (en) | 2000-08-22 |
EP1007077A1 (en) | 2000-06-14 |
ATE444760T1 (en) | 2009-10-15 |
EP1007077B1 (en) | 2009-10-07 |
AU5910998A (en) | 1998-08-03 |
DE69841217D1 (en) | 2009-11-19 |
JP2001511770A (en) | 2001-08-14 |
EP1007077A4 (en) | 2003-07-23 |
CA2277911C (en) | 2010-09-14 |
JP4578578B2 (en) | 2010-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6107281A (en) | Compounds and their combinations for the treatment of influenza infection | |
US4346103A (en) | Treatment for arthritis and substances for use in such treatment | |
EP1371640B1 (en) | Novel a-lipoic acid derivative and use thereof | |
US4871742A (en) | Process and pharmaceutical compositions for the treatment of glaucoma | |
JP4731321B2 (en) | Composition for preventing or treating viral infection | |
KR20040101576A (en) | Calcium-containing tissue strengthening agents and use thereof | |
KR100585242B1 (en) | Compounds and their combinations for the treatment of influenza infection | |
AU689603B2 (en) | A pharmaceutical composition for the prevention and/or treatment of viral infections and optionally inflammations as well as a method for the treatment thereof | |
JP2010265217A (en) | Salivary secretion promoter and composition for salivary secretion promotion | |
JP4300409B2 (en) | Anti-influenza virus agent using chlorogenic acid ester derivative | |
US11759435B2 (en) | Dihydrochalcone derivatives influencing inflammatory states | |
EP1701973B1 (en) | Glutathione derivatives and their uses for the treatment of viral diseases | |
US6034126A (en) | Method for treating glycol poisoning | |
WO2022158602A1 (en) | Composition having antiviral activity | |
EP0087142B1 (en) | The use of alpha, alpha-dialkyl adamanthylethylamines to treat measles | |
US4783449A (en) | Hydrosoluble pharmaceutical compositions containing salts of (-)cis-1,2-epoxypropylphosphonic acid with aminoacids | |
WO1997046229A1 (en) | New use of derivatives of cystine | |
CN112972441A (en) | Application of monocarbonyl curcumin compound in preparation of medicine for preventing and treating periodontitis | |
EP1596851A1 (en) | The use of sodium 2-mercaptoethanesulfonate as antiviral agent | |
EP0753309A2 (en) | Preparation of lactoferrin (or analogous proteins) and desferrioxamine methanesulfonate (or other metal ion chelators) for the therapy of viral infectious diseases | |
GB2165152A (en) | Hydrosoluble antibiotic pharmaceutical compositions | |
NL8602139A (en) | Inhibition of parathyroid hormone secretion. | |
JP2018052910A (en) | Antiviral action promoting composition | |
EP1274679A1 (en) | Bifunctional inhibitors of malarial proteases and uses thereof | |
JP2003160492A (en) | Enhancer of germicidal activity of leukocyte containing pterin derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG BR CA CN CZ HU IL JP KP MX NO NZ PL RO SG SI SK UA VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2277911 Country of ref document: CA Ref country code: CA Ref document number: 2277911 Kind code of ref document: A Format of ref document f/p: F Ref country code: JP Ref document number: 1998 531111 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998902446 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998902446 Country of ref document: EP |